$CLS

MIONIS ROBERT sold $3.5M of CLS (indirect holdings)

MIONIS ROBERT (Chief Executive Officer) sold 9,543 indirectly-held shares of CELESTICA INC (CLS) at an average of $367.49 ($360.47–$374.49, $3.51M total) across 11 trades on 2026-07-31 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MIONIS ROBERT
Published Aug 3, 2026, 10:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CLS
Neutral
high confidence
Mentioned
$CLS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLSNeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but 10b5-1 sales are generally less informative about near-term fundamentals. Without accompanying guidance, contract, or earnings news, the impact is likely limited.

02

Market read

A scheduled CEO 10b5-1 sale of about $3.5M of CLS shares is disclosed, offering limited incremental trading signal absent other catalysts.

03

What to watch

The filing does not clarify whether other insiders sold/bought around the same window, nor does it provide context on total insider ownership changes beyond the post-transaction figure.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-03, transaction dated 2026-07-31

Background

The article is an SEC Form 4 insider transaction disclosure for Celestica (CLS) by CEO Mionis Robert, marked as an indirect open-market sale under a 10b5-1 plan.

Company-level read

Ticker impact

$CLSNeutralHigh confidence
Context

Celestica CEO Mionis Robert sold $3.51M of CLS shares via a 10b5-1 plan on 2026-07-31, disclosing indirect holdings after sale.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless paired with other catalysts.

Evidence & confidence

The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article contains no new operational, financial, or regulatory developments.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Celestica Inc.

    Subject of the Form 4 insider transaction disclosure (CLS).

  • Mionis Robert

    CEO and officer/director who sold shares under a pre-arranged 10b5-1 plan.

Related articles

$CLSMedAI 8/10

Celestica Completes Equity Offering

Celestica Inc. (NYSE: CLS, TSX: CLS) said it completed its equity offering of 9,677,419 common shares at $310 per share. Including the underwriters’ option, 11,129,031 shares were sold for about $3.45 billion in gross proceeds. Net proceeds will be used for working capital, capital expenditures, and general corporate purposes.

$CLSHighAI 9/10

Celestica Falls After Pricing $3 Bln Equity Offering

Celestica Inc. (CLS) shares fell nearly 12% after the company priced a $3.0 billion public equity offering. According to the company, it sold 9.68 million common shares at $310 each, raising expected gross proceeds of $3.0 billion, and gave underwriters a 30-day option for up to 1.45 million additional shares. CLS traded around $319.48, down about $43.28.

$CLSHighAI 9/10

Why is Celestica stock sliding today?

Celestica (CLS) shares fell 13.7% after the company priced a $3 billion common stock offering at $310 per share, down from the prior close of $362.76. Celestica plans to sell about 9.68 million treasury shares, with underwriters able to buy 1.45 million more. Management said the raise supports AI compute and networking demand.

$CLSMedAI 8/10

Celestica Announces Pricing of Equity Offering

Celestica Inc. (NYSE: CLS, TSX: CLS) priced an equity offering of 9,677,419 common shares at $310 per share. Gross proceeds are expected at about $3.0 billion before underwriting discounts and expenses. Underwriters have a 30-day option to buy up to 1,451,612 additional shares. Net proceeds will fund working capital and capital expenditures, among other purposes. Closing is expected around Aug. 7, 2026.